Cetuximab

EGF, cleaved from pro-EGF at the basolateral membrane of distal convoluted tubule (DCT) cells, is a magnesiotropic hormone: it binds basolateral EGFR to sustain the apical channel TRPM6, the principal route of Mg2+ entry (Groenestege, JCI 2007; Ellison, NDT 2008). Cetuximab blocks EGFR and removes this stimulus, so TRPM6 activity falls and the DCT can no longer reclaim filtered magnesium — producing renal magnesium wasting with an inappropriately high fractional excretion of Mg despite hypomagnesemia. GFR and serum creatinine are preserved: this is a tubular electrolyte-handling defect, not structural AKI. In-vitro work also implicates reduced intestinal (gut TRPM6) Mg absorption (Pietropaolo, Nutrients 2020). Magnesium depletion secondarily impairs PTH secretion/action and distal potassium retention, producing hypocalcemia and hypokalemia that stay refractory until magnesium is restored.

Most often an asymptomatic laboratory finding on routine chemistry. Symptomatic hypomagnesemia causes fatigue, muscle cramps, tremor, paresthesias, tetany and, when severe, seizures or cardiac arrhythmia (QT prolongation, torsades). Because magnesium is required for PTH action and distal K+ handling, patients frequently show accompanying hypocalcemia and hypokalemia that resist calcium/potassium repletion alone. Serum creatinine and GFR remain normal.

Repletion, not dose reduction, is the mainstay — the antibody is not renally cleared and cetuximab dosing is not altered for the electrolyte defect. Oral magnesium (e.g., magnesium oxide or glycinate) is first-line for mild deficits but is limited by diarrhea and by the same TRPM6 blockade in the gut. Moderate-to-severe or symptomatic hypomagnesemia needs intravenous magnesium sulfate, often recurrently (e.g., several grams IV every 1-2 weeks), because ongoing renal wasting makes repletion transient while therapy continues. Correct magnesium first: coexisting hypocalcemia and hypokalemia are frequently refractory until magnesium is restored. A potassium-sparing diuretic (amiloride) is sometimes used to blunt distal Mg loss in refractory cases. Grade 3-4 or symptomatic (arrhythmia, tetany) hypomagnesemia may warrant holding cetuximab until corrected. Magnesium supplementation does not appear to impair cetuximab's antitumor efficacy (Pietropaolo, Nutrients 2020).Lesion-level management framework

No renal dose adjustment. Cetuximab is a ~152 kDa IgG1 antibody cleared by reticuloendothelial catabolism, not glomerular filtration, so kidney function does not change its exposure and no reduction is needed in CKD. The management problem is electrolyte monitoring and repletion, not dosing.

Not dialyzable — an IgG1 monoclonal antibody is far too large to cross dialysis membranes and stays confined to the vascular compartment. Hemodialysis neither removes cetuximab nor corrects the underlying tubular defect; note that dialysis can itself remove magnesium, so Mg status still needs attention in dialysis patients.

The hallmark is renal magnesium wasting — an inappropriately high fractional excretion of magnesium (FEMg >2-4%, or ongoing urinary Mg despite hypomagnesemia) with preserved GFR. Contrast with: GI/dietary losses (diarrhea, malabsorption) where the kidney conserves appropriately and FEMg is low (<2%); PPI-associated hypomagnesemia (also gut TRPM6-mediated — check the med list); cisplatin tubulopathy (renal Mg wasting too, but usually accompanied by a rising creatinine/AKI and multi-electrolyte loss); Gitelman syndrome or thiazide/loop diuretics (renal Mg + K wasting in a chronic/drug context); and refractory hypocalcemia/hypokalemia that is actually magnesium-dependent and corrects only once Mg is replaced.